Fludarabine

Generic Name: Fludarabine

Brand Names: Fludara

Drug Type: Small Molecule

Chemical Formula: C_₁₀H_₁₂FN_₅O_₄

CAS Number: 21679-14-1

Unique Ingredient Identifier: P2K93U8740

Background: Fludarabine is a chemotherapeutic agent used in the treatment of hematological malignancies. It is commonly marketed under the brand name Fludara.

Indication: For the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to or whose disease has progressed during treatment with at least one standard alkylating-agent containing regimen

Associated Conditions: B-cell chronic lymphocytic leukemia/prolymphocytic leukemia/small lymphocytic lymphoma refractory, Refractory Non-Hodgkin's lymphoma

Associated Therapies: -

Clinical Trials

A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

Phase 2

Completed

Conditions: Hematological Malignancies

Interventions: Radiation: Total Body Irradiation
Drug: Cyclophosphamide
Drug: Tacrolimus
Drug: Mycophenolate mofetil
Drug: Fludarabine
Drug: Busulfan
Genetic: Hematopoietic stem cell transplantation

First Posted Date: 2011-05-06

Last Posted Date: 2022-12-21

Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Target Recruit Count: 80

Registration Number: NCT01349101

Locations: 🇺🇸
Thomas Jefferson University, Philadelphia, Pennsylvania, United States

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Phase 1

Completed

Conditions: Neoplasms

Interventions: Drug: NY-ESO-1(c259)T Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2011-04-27

Last Posted Date: 2021-06-30

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 50

Registration Number: NCT01343043

Locations: 🇺🇸
GSK Investigational Site, Houston, Texas, United States

Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

Phase 1

Completed

Conditions: Multiple Myeloma
Leukemia
Hodgkin's Lymphoma
Myelodysplastic Syndrome(MDS)
Non Hodgkin's Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Radiation: Total body irradiation
Drug: Mycophenolate Mofetil
Drug: Tacrolimus 90
Drug: Tacrolimus 120
Drug: Tacrolimus 60
Biological: Bone marrow transplant

First Posted Date: 2011-04-27

Last Posted Date: 2018-10-17

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 127

Registration Number: NCT01342289

Locations: 🇺🇸
Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States

Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

Phase 2

Completed

Conditions: Myelodysplastic Syndrome
Acute Lymphocytic Leukemia
Acute Myelogenous Leukemia
Chronic Myelogenous Leukemia
Chronic Myelomonocytic Leukemia

Interventions: Procedure: First Allogeneic Bone Marrow Transplant (BMT)
Drug: Leuprolide
Drug: 18F FLT
Drug: Cyclophosphamide
Drug: Methotrexate
Drug: Busulfan
Drug: Tacrolimus
Drug: Fludarabine
Radiation: Total Body Irradiation
Procedure: Second Allogeneic Bone Marrow Transplantation

First Posted Date: 2011-04-20

Last Posted Date: 2021-03-18

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 76

Registration Number: NCT01338987

Locations: 🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States
🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
🇺🇸
University of Oklahoma, Oklahoma City, Oklahoma, United States

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Phase 2

Active, not recruiting

Conditions: Metastatic Melanoma
Skin Cancer

Interventions: Drug: Aldesleukin
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Young TIL
Radiation: Total Body Irradiation (TBI)

First Posted Date: 2011-03-21

Last Posted Date: 2024-12-27

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 102

Registration Number: NCT01319565

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Study of Fludarabine Drug Exposure in Pediatric Bone Marrow Transplantation

Completed

Conditions: Hematologic Malignancies
Fanconi Anemia
Nonmalignant Diseases
Immunodeficiencies
Genetic Inborn Errors of Metabolism
Hemoglobinopathies
Thalassemia
Sickle Cell Disease

Interventions: Drug: Fludarabine

First Posted Date: 2011-03-16

Last Posted Date: 2021-10-04

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 67

Registration Number: NCT01316549

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

Phase 3

Conditions: Follicular Lymphoma

Interventions: Drug: Rituximab
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Vincristine
Drug: Prednisolone

First Posted Date: 2011-02-25

Last Posted Date: 2011-05-06

Lead Sponsor: University of Liverpool

Target Recruit Count: 680

Registration Number: NCT01303887

Locations: 🇬🇧
Queen's Hospital, Burton, Burton-upon-Trent, United Kingdom
🇬🇧
Princess Royal Hospital, Bromley, Hayes, United Kingdom
🇬🇧
Trafford General Hospital, Davyhulme, United Kingdom

and more 70 locations

A Study of Obinutuzumab (GA101; RO5072759) in Combination With Chemotherapy in Participants With Previously Untreated Chronic Lymphocytic Leukemia (CLL) (GALTON)

Phase 1

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Fludarabine
Drug: Bendamustine
Drug: Obinutuzumab
Drug: Cyclophosphamide

First Posted Date: 2011-02-21

Last Posted Date: 2017-02-02

Lead Sponsor: Genentech, Inc.

Target Recruit Count: 41

Registration Number: NCT01300247

Yttrium-90 Anti-CD45 Monoclonal Antibody BC8 Followed by Donor Stem Cell Transplant in Treating Patients With High-Risk AML, ALL, or MDS

Phase 1

Completed

Conditions: Chronic Myelomonocytic Leukemia
Previously Treated Myelodysplastic Syndrome
Recurrent Adult Acute Lymphoblastic Leukemia
Recurrent Adult Acute Myeloid Leukemia
Refractory Anemia With Excess Blasts
Secondary Acute Myeloid Leukemia

Interventions: Procedure: Allogeneic Bone Marrow Transplantation
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclosporine
Drug: Fludarabine Phosphate
Biological: Indium In 111 Anti-CD45 Monoclonal Antibody BC8
Other: Laboratory Biomarker Analysis
Drug: Mycophenolate Mofetil
Procedure: Peripheral Blood Stem Cell Transplantation
Other: Pharmacological Study
Radiation: Total-Body Irradiation
Radiation: Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8

First Posted Date: 2011-02-21

Last Posted Date: 2019-12-10

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 16

Registration Number: NCT01300572

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

A Study to Compare Subcutaneous Versus Intravenous MabThera (Rituximab) in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia

Phase 1

Completed

Conditions: Lymphocytic Leukemia, Chronic

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Drug: rituximab [MabThera]

First Posted Date: 2011-02-09

Last Posted Date: 2018-12-19

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 240

Registration Number: NCT01292603

Locations: 🇧🇷
Hospital das Clinicas - FMUSP, Sao Paulo, SP, Brazil
🇦🇷
HOSPITAL PRIVADO - CENTRO MEDICO DE CÓRDOBA; Dpto Oncología, Córdoba, Argentina
🇩🇪
Klinik der Uni zu Köln; Klinik für Innere Medizin, Köln, Germany

and more 81 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy